Illumina Inc. (NASDAQ:ILMN) is a prominent player in the field of genetic sequencing and analysis. The company is known for its innovative technologies that enable researchers and healthcare professionals to explore the human genome. Illumina's main competitors include companies like Thermo Fisher Scientific and Agilent Technologies, which also operate in the life sciences sector.
On December 15, 2025, Barclays set a price target of $110 for Illumina, while the stock was trading at $134.85. This suggests a potential downside of approximately -18.43% from the target. Despite this, Illumina is recognized as a top momentum stock by Zacks Investment Research, indicating its potential for long-term growth.
Zacks highlights Illumina's strong momentum score, which suggests a high likelihood of outperforming the market. This is significant for investors seeking long-term gains. The Zacks Rank and Zacks Industry Rank provide daily updates and access to top-ranked stocks, helping investors make informed decisions.
Illumina's current stock price is $134.85, reflecting a decrease of 1.59, or -1.17%. The stock has traded between $134.12 and $137.09 today. Over the past year, it reached a high of $153.06 and a low of $68.70. With a market capitalization of approximately $20.61 billion, Illumina remains a significant player in the industry.
The trading volume for Illumina is 1,265,723 shares, indicating active investor interest. Despite the price target set by Barclays, Illumina's strong momentum score and market position make it an attractive option for investors looking for long-term growth opportunities.
